- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02619539
Shock Index To DEtect Low Plasma Fibrinogen In Trauma (SIDE) (SIDE)
March 22, 2017 updated by: Josef Skola, Masaryk Hospital Krajská zdravotní a.s.
Shock-index is potentially an easy tool to estimate the risk of hypofibrinogenemia without the need to perform other potentially time consuming investigations.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Hypofibrinogenemia is common in severe trauma and below the threshold of 2.3 g/l is associated with increased mortality.
Although guidelines for management of the trauma induced coagulopathy does not recommend any specific timing of fibrinogen substitution, several papers suggest that early substitution might be associated with improved outcome.
Laboratory measurement of plasma fibrinogen level, thromboelastometry and/or its estimation based on base excess, hemoglobin level, Injury Severity Score or combinations require diagnostic procedures that are associated with with a certain time delay and prolongs the time to fibrinogen substitution.
Study Type
Observational
Enrollment (Actual)
280
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Plzen, Czech Republic
- University Hospital in Plzen
-
Usti nad Labem, Czech Republic, 40001
- Masaryk hospital in Usti nad Labem
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Patient having / suspected to have severe trauma admitted to participating centres.
Description
Inclusion Criteria:
- patient having / suspected to have severe trauma transported to participating centers by cooperating Emergency Medical System organizations
Exclusion Criteria:
- possible alterations of plasma fibrinogen level in the time of trauma (inflammatory disease, malignant disease, pregnancy)
- administration of fibrinogen containing products (fresh frozen plasma, fibrinogen concentrate, cryoprecipitate) before sampling blood for fibrinogen level
- circumstances possibly interfering with plasma fibrinogen level measurement (prior the administration of hydroxyethylstarches)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Trauma patients
All patients having / suspected to have severe trauma injuries admitted to participating centers.
|
plasma fibrinogen measurement
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of subjects that have plasma fibrinogen <2.3 g.l-1 on admission among those with shock-index >1.
Time Frame: On admission
|
On admission
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Josef Skola, Dr., Masaryk Hospital Usti nad Labem
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Hagemo JS, Stanworth S, Juffermans NP, Brohi K, Cohen M, Johansson PI, Roislien J, Eken T, Naess PA, Gaarder C. Prevalence, predictors and outcome of hypofibrinogenaemia in trauma: a multicentre observational study. Crit Care. 2014 Mar 26;18(2):R52. doi: 10.1186/cc13798.
- Spahn DR, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernandez-Mondejar E, Filipescu D, Hunt BJ, Komadina R, Nardi G, Neugebauer E, Ozier Y, Riddez L, Schultz A, Vincent JL, Rossaint R. Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care. 2013 Apr 19;17(2):R76. doi: 10.1186/cc12685.
- Levy JH, Szlam F, Tanaka KA, Sniecienski RM. Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding. Anesth Analg. 2012 Feb;114(2):261-74. doi: 10.1213/ANE.0b013e31822e1853. Epub 2011 Sep 29.
- Schochl H, Maegele M, Solomon C, Gorlinger K, Voelckel W. Early and individualized goal-directed therapy for trauma-induced coagulopathy. Scand J Trauma Resusc Emerg Med. 2012 Feb 24;20:15. doi: 10.1186/1757-7241-20-15.
- Schlimp CJ, Voelckel W, Inaba K, Maegele M, Ponschab M, Schochl H. Estimation of plasma fibrinogen levels based on hemoglobin, base excess and Injury Severity Score upon emergency room admission. Crit Care. 2013 Jul 12;17(4):R137. doi: 10.1186/cc12816.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2016
Primary Completion (Actual)
February 28, 2017
Study Completion (Actual)
February 28, 2017
Study Registration Dates
First Submitted
November 30, 2015
First Submitted That Met QC Criteria
November 30, 2015
First Posted (Estimate)
December 2, 2015
Study Record Updates
Last Update Posted (Actual)
March 24, 2017
Last Update Submitted That Met QC Criteria
March 22, 2017
Last Verified
March 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KAPIM-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Trauma, Multiple
-
Wonju Severance Christian HospitalNational Research Foundation of KoreaCompletedTrauma Injury | Trauma, MultipleKorea, Republic of
-
University Hospital, Basel, SwitzerlandRecruiting
-
Norwegian University of Science and TechnologySt. Olavs HospitalTerminatedTrauma, Multiple | Trauma Severity Indices | Injuries, Multiple | Norway/Epidemiology | Trauma Centers/Statistics & Numerical Data
-
Prof. Dr. Cemil Tascıoglu Education and Research...CompletedTrauma Injury | Trauma, MultipleTurkey
-
Humacyte, Inc.CompletedTrauma | Trauma Injury | Trauma, Multiple | Trauma BluntUkraine
-
Oslo University HospitalUniversity of Oslo; Sunnaas Rehabilitation Hospital; South-Eastern Norway Regional...RecruitingTrauma Injury | Trauma, Multiple | PolytraumaNorway
-
Al-Nahrain UniversityRecruitingMultiple Trauma/InjuriesIraq
-
St. Martin De Porress HospitalRecruitingMultiple Trauma/InjuriesTaiwan
-
Second Affiliated Hospital, School of Medicine,...Recruiting
Clinical Trials on plasma fibrinogen measurement
-
University Hospital Inselspital, BerneCompleted
-
Grifols Therapeutics LLCInstituto Grifols, S.A.CompletedCongenital AfibrinogenemiaIndia, United States, Italy, Lebanon
-
Masaryk Hospital Krajská zdravotní a.s.CompletedCoagulation Disorder | Multiple Trauma | Coagulation Defect; Acquired | Coagulation Factor DeficiencyCzechia
-
BiotestICON Clinical Research; PRA Health SciencesCompletedBleeding Disorder | Hypofibrinogenemia; AcquiredBelgium, Czechia, Germany, Poland, Spain, Switzerland, United Kingdom
-
University Health Network, TorontoSunnybrook Health Sciences Centre; Canadian Institutes of Health Research (CIHR) and other collaboratorsRecruitingCoagulopathy | Traumatic Hemorrhage | Massive HemorrhageCanada
-
OctapharmaCompletedCongenital Fibrinogen Deficiency | AfibrinogenemiaIran, Islamic Republic of, United States, Bulgaria, India, Switzerland, United Kingdom
-
University of EdinburghCSL Behring; NHS LothianCompletedCoagulopathy in Patients Having Thoraco-Abdominal Aneurysm RepairUnited Kingdom
-
The First Hospital of Jilin UniversityNot yet recruitingAdult | Patients Admitted to the ICU | Expected Hospital Stay ≥48 Hours
-
Changi General HospitalCompletedObstructive Sleep Apnea | Pheochromocytoma | Catecholamine; SecretionSingapore
-
University Medical Centre LjubljanaUnknownGuillain-Barre Syndrome | Humoral Rejection | CIDP | Miller Fisher Syndrome | Good Pasture Syndrome | Hyperviscosity SyndromeSlovenia